MindMed Upsizes Previously Announced Bought Deal Public Offering
NEW YORK, Dec. 15, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) (“MindMed” or the “Company”), a leading psychedelic medicine biotech company, is pleased to announce that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp. (the “Lead Underwriter”). The Lead Underwriter has […]
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
NEW YORK, Dec. 14, 2020 /PRNewswire/ — MindMed (NEO: MMED,OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder. The successful completion of this engagement with […]
MindMed Upsizes Previously Announced Bought Deal Public Offering
NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp. (the “Lead Underwriter”). The Lead Underwriter […]
MindMed Announces $25 Million Bought Deal Public Offering
NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the “Lead Underwriter”) pursuant to which the Lead Underwriter has agreed, on behalf of a […]
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and […]
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
NEW YORK and BASEL, Switzerland, Nov. 16, 2020 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its protocol design for a Phase 2a clinical trial evaluating microdoses of LSD in the treatment of adult ADHD from the Swiss and Dutch health authorities. MindMed has also successfully submitted a […]
MindMed Announces Q3 2020 Financial Results; Cash Reserves Total $37.8 million USD ($50.1 million CAD) Post October Financing
TORONTO, Nov 13, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system […]
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
BASEL, Switzerland, Sept. 24, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading drug development company for psychedelic inspired medicines, announces that the company has been conducting R&D work on psilocybin in collaboration with the University Hospital Basel’s Liechti Lab in a study to better understand and compare the altered states of […]
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
NEW YORK, Sept. 21, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ”). As part of this up-listing strategy in the United States, MindMed has submitted an application […]
MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics ResearcherDr. Matthias Liechti as Principal Investigator BASEL, Switzerland, June 2, 2020 /PRNewswire/ — Mind Medicine(MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic […]
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
MindMed Further Expands R&D Collaboration with University Hospital Basel’s Liechti Lab with Plans To Develop Next-Gen Psychedelic Therapies Combining LSD and MDMA NEW YORK, May 27, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D pipeline. The […]
MindMed reports First Quarter 2020 Results
TORONTO, May 14, 2020: Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED, OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its unaudited condensed consolidated financial statements (the “Financial Statements”) and accompanying management’s discussion and analysis (the “MD&A”) for the quarter ended March 31, 2020. All financial […]
MindMed Advances Phase 2 LSD Microdosing Trial
TORONTO – May 11, 2020 – Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ( (“MindMed” or the “Company”) is pleased to announce that, on May 8, 2020, it has entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide (“LSD”) in adult patients with […]
MindMed NEO:MMED
Mindmed is developing therapeutic treatments from psychedelic substances to improve health and wellness. Assembling the most compelling IP portfolio of psychedelic inspired medicines for FDA clinical trials & commercialization. The legalization of psychedelic inspired medicines will be different than cannabis. FDA will regulate as drug therapies using clinical trials.